Solid Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

• Solid Biosciences Inc SLDB.OQ reported a quarterly adjusted loss of 59 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -64 cents. The mean expectation of twelve analysts for the quarter was for a loss of 56 cents per share. Wall Street expected results to range from -88 cents to -38 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Solid Biosciences Inc's reported EPS for the quarter was a loss of 59 cents​.

• The company reported a quarterly loss of $39.28 million.

• Solid Biosciences Inc shares had fallen by 30.0% this quarter and lost 35.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 28.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00

This summary was machine generated from LSEG data May 16 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)